“Global Clinical Trial Supply and Logistics Market for Pharma set to grow to $15bn by 2025” says new Visiongain report

24 April 2020
Pharma

Visiongain has launched a new pharma report Clinical Trial Supply and Logistics Market for Pharma: Forecasts by Type (Clinical Trial Manufacturing (Clinical Trial Packaging, Others), Clinical Trial Logistics and Distribution (Clinical Trial Cold Chain Logistics, Others), Clinical Trial Supply Chain Management), by End Users (CRO’s, Pharma & Biotech, Others (Academics, Research Institutes etc.)) PLUS COVID-19 Impact Analysis.

Demands for increasingly complex and expensive clinical trials have led drug developers to look to external service providers to source clinical trial materials and deliver them to investigator sites. Demand for biological and orphan drugs will be one of the factors that drive the clinical trial supply and logistics market for pharma. Rising need for cold chain logistics will increase demand for new packaging and monitoring technologies that offer lower-cost solutions, including reusable packaging and phase change materials that allow cooling for more-specific temperature ranges.

The lead analyst of the report commented "The outbreak of COVID-19 has impacted the clinical trials industry causing delays to the 336,444 clinical trials listed on the Clinical Trials website. The impact of COVID-19 has shifted the focus of biopharmaceutical companies to developing a vaccine for COVID-19 and thus potentially disrupting clinical trials for other diseases.

As the pandemic increases the demand for more effective pharmaceutical and medical products will rise. This requires clinical trial supply and logistic service providers to work closely with their end users and safeguard against clinical supply disruptions. Visiongain anticipates that this will create new opportunities for the market players in order to utilise on demand warehousing with the outsourced workforce for value addition & order fulfilment."

Leading companies featured in the report include Almac Group, Amatsigroup, Catalent, DHL, FedEx, Fisher Clinical Services, Marken. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever